Revolutionizing the Way We Treat HCV: STAT-C

Gastroenterology

Revolutionizing the Way
We Treat HCV: STAT-C

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

OR

You may also be interested in Hepatitis C: From Scientific Foundations to New Vistas in Treatment

Dear Colleague,

Specifically targeted antiviral therapy for HCV (STAT-C) is advancing in clinical development and will revolutionize the way we treat chronic HCV infection. The future clinical implications of these agents have a potential reach far beyond that of providing alternative options to today's standard-of-care therapy. Early clinical trials of STAT-C agents suggest a future with the hope of significantly higher rates of efficacy and significantly lower durations of treatment.

The faculty of Revolutionizing the Way We Treat HCV: STAT-C will lead you through a clinical and scientific assessment of these new agents. Drawing on decades of expertise in clinical and research virology, gastroenterology and hepatology, Drs. Rice, Pawlotsky, and McHutchison will join me in examining the molecular foundation for the design of STAT-C agents, identifying methodology to define and quantify resistance, presenting the most recent efficacy, safety, and resistance data, and projecting the implications of these developments within the context of your clinical practice.

We hope you enjoy this timely and relevant information!

Sincerely,

Ira M. Jacobson, MD

CHAIR
Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director of the Center for the Study of Hepatitis C Weill Medical College of Cornell University New York, New York
FACULTY
John G. McHutchison, MD, FRACP Director, Gastroenterology/Hepatology Research Duke Clinical Research Institute Professor of Medicine Duke University Medical Center Durham, North Carolina
Jean-Michel Pawlotsky, MD, PhD Professor of Medicine Director, French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology and INSERM U635 Hôpital Henri Mondor Université de Paris XII Créteil, France
Charles M. Rice, PhD Maurice R. and Corinne P. Greenberg Professor of Virology Scientific and Executive Director, Center for the Study of Hepatitis C Head, Laboratory for Virology and Infectious Disease The Rockefeller University New York, New York

Introduction
Ira M. Jacobson, MD

What's New in HCV Virology
Charles M. Rice, PhD

Revolution in anti-HCV Treatment: STAT-C Therapies
John G. McHutchison, MD, FRACP

Viral Resistance: Translating Science into Clinical Application
Jean-Michel Pawlotsky, MD, PhD

Clinical Implications of STAT-C Agents in the Future
Ira M. Jacobson, MD

Q & A
Panel

Conclusion
Ira M. Jacobson, MD

top

TARGET AUDIENCE

This CME activity is designed for gastroenterologists, hepatologists, and other clinicians who treat patients with HCV infection.

ACTIVITY GOAL

The goal of this activity is to provide clinicians with cutting-edge information on anti-HCV treatment challenges, molecular approaches to anti-HCV therapy, and new pipeline protease and polymerase inhibitors and the role that these treatments may play in the future.

LEARNING OBJECTIVES

Integrate knowledge of HCV biology, including receptor interactions, cell culture systems, mechanisms of replication, and mechanism of action of protease and polymerase inhibitors in order to assess the potential role of specifically targeted anti-HCV therapies for HCV-infected patients.
Formulate a critical assessment of the latest efficacy and safety data on protease and polymerase inhibitors in order to distinguish between these agents as future therapeutic options in the treatment of patients with HCV infection.
Analyze emerging data on viral resistance to specifically targeted anti-HCV therapies to better understand the clinical implications of resistance and identify potential strategies to minimize its impact on response in HCV-infected patients.
Assess the potential clinical implications of new anti-HCV agents in patients with chronic hepatitis C—in terms of rate and predictors of response, toxicity, and duration—using findings from clinical trials evaluating these agents.

top

CME INFORMATION—PHYSICIANS

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Ira M. Jacobson, MD, has received grant/research support from Bristol-Myers Squibb Company, Coley Pharmaceuticals, Gilead Sciences, Inc, GlobeImmune, Idenix Pharmaceuticals, InterMune Inc, Novartis Pharmaceuticals Corporation, Schering-Plough Corporation, Valeant Pharmaceuticals, and Vertex Pharmaceuticals, Inc; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Celera Genomics, Coley Pharmaceuticals, Gilead Sciences, Inc, Idenix Pharmaceuticals, InterMune Inc, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Schering-Plough Corporation, Valeant Pharmaceuticals, and Vertex Pharmaceuticals, Inc; and is on the speakers bureaus of Bristol-Myers Squibb Company, Gilead Sciences, Inc, and Schering-Plough Corporation.

John G. McHutchison, MD, FRACP, has received grant/research support from Akros Pharma Inc, Amgen Inc, Bayer Pharmaceuticals, Biomedicines, Bristol-Myers Squibb Company, Coley Pharmaceuticals, Inc, Fujisawa Healthcare, Inc, Gilead Sciences, Inc, Human Genome Sciences, IDUN Pharmaceuticals, Isis Pharmaceuticals, Inc, Ortho Diagnostic Systems, Inc, Prometheus Laboratories, Ribozyme Pharmaceuticals, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmaceuticals, Triangle Pharmaceuticals Inc, and Vertex Pharmaceuticals, Inc; and is a consultant for and/or on the speakers bureaus and advisory boards of Amgen Inc, Anadys Pharmaceuticals, Inc, Centocor, Inc, Coley Pharmaceuticals, GlaxoSmithKline, Idenix Pharmaceuticals, Inc, InterMune Inc, Isis Pharmaceuticals, Inc, National Genetics Institute Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Prometheus Laboratories, Ribozyme Pharmaceuticals, Inc, Schering-Plough Corporation, Valeant Pharmaceuticals, Vertex Pharmaceuticals, Inc, and XTL Biopharmaceuticals Ltd; and is on the hepatitis C anti-viral scientific resource board of Peregrine Pharmaceuticals, Inc.

Jean-Michel Pawlotsky, MD, PhD, has received grant/research support from Gilead Sciences, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, and Vertex Pharmaceuticals, Inc; is a consultant for and/or on the advisory boards of Abbott Laboratories, Bristol-Myers Squibb Company, Gilead Sciences, Inc, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Schering-Plough Corporation, Valeant Pharmaceuticals, Vertex Pharmaceuticals, Inc, and XTL Biopharmaceuticals Ltd; and is on the speakers bureaus of Bristol-Myers Squibb Company, Gilead Sciences, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, and Vertex Pharmaceuticals, Inc.

Charles M. Rice, PhD, is a consultant for AlphaVax, Inc, Chiron Corporation, Novartis Pharmaceuticals Corporation, Vertex Pharmaceuticals Inc, and XTL Biopharmaceuticals, Ltd; is on the advisory boards of Chiron Corporation, Novartis Pharmaceuticals Corporation, Vertex Pharmaceuticals Inc, and XTL Biopharmaceuticals, Ltd; and has ownership interest in AlphaVax, Inc, Apath LLC, and ViroPharma Incorporated.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME activity is supported by an educational grant from Vertex Pharmaceuticals Incorporated.

top

1778